

Alison J Moskowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4027449/publications.pdf>

Version: 2024-02-01

100
papers

3,095
citations

201385

27
h-index

168136

53
g-index

100
all docs

100
docs citations

100
times ranked

3276
citing authors

#	ARTICLE	IF	CITATIONS
1	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1183-1194.	0.6	276
2	Normalization of pre-ASCT, FDG-PET imaging with second-line, non-â€“cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 1665-1670.	0.6	258
3	PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 284-292.	5.1	230
4	Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2010, 116, 4934-4937.	0.6	228
5	Activity of the PI3K-Î³ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. <i>Blood</i> , 2018, 131, 888-898.	0.6	224
6	How I treat the peripheral T-cell lymphomas. <i>Blood</i> , 2014, 123, 2636-2644.	0.6	132
7	Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 2196-2203.	0.6	111
8	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021, 138, 427-438.	0.6	109
9	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	0.8	97
10	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	2.8	81
11	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	2.5	64
12	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1458-1464.	0.6	61
13	Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study. <i>Blood</i> , 2016, 128, 181-181.	0.6	56
14	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4640-4647.	2.5	50
15	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	0.6	46
16	Central nervous system involvement in T-cell lymphoma: A single center experience. <i>Acta OncolÃ³gica</i> , 2016, 55, 561-566.	0.8	44
17	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
18	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	2.0	43

#	ARTICLE	IF	CITATIONS
19	Recurrent somatic JAK3 mutations in NK-cell enteropathy. <i>Blood</i> , 2019, 134, 986-991.	0.6	42
20	Prospective Study of ^{18}F -Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 728-734.	2.8	41
21	Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 187-197.	2.5	40
22	Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. <i>Leukemia and Lymphoma</i> , 2016, 57, 2575-2583.	0.6	39
23	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	0.6	38
24	Cutaneous manifestations of human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: A single-center, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 293-301.e2.	0.6	35
25	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	2.8	35
26	Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 430-439.	0.6	34
27	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	0.8	32
28	Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 1002-1010.	3.2	30
29	The Combination of Duvelisib, a PI3K- γ , δ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. <i>Blood</i> , 2018, 132, 683-683.	0.6	28
30	Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 175, 440-447.	1.2	27
31	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	2.8	25
32	T α cell receptor α expression and β $^+$ T α cell infiltrates in primary cutaneous β $^+$ T α cell lymphoma and other cutaneous T α cell lymphoproliferative disorders. <i>Histopathology</i> , 2018, 73, 653-662.	1.6	24
33	Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 477-486.	1.8	24
34	Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma. <i>Journal of Oncology Practice</i> , 2019, 15, 137-143.	2.5	24
35	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	1.3	21
36	A Phase Ib/Ia Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2991-2991.	0.6	21

#	ARTICLE	IF	CITATIONS
37	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4019-4019.	0.6	20
38	The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸ F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1424-1430.	2.8	20
39	Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 1066-1076.	0.4	19
40	Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2020, 136, 33-34.	0.6	19
41	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 97-105.	0.2	18
42	Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. <i>Blood</i> , 2019, 134, 238-238.	0.6	18
43	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	3.2	17
44	Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. <i>Leukemia and Lymphoma</i> , 2020, 61, 3331-3341.	0.6	17
45	Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. <i>American Journal of Hematology</i> , 2021, 96, 1211-1222.	2.0	16
46	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas. <i>Blood</i> , 2017, 130, 821-821.	0.6	15
47	Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 970-976.	0.6	14
48	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	3.2	13
49	Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 1861-1870.	0.6	12
50	<i>In Vitro</i> , <i>In Vivo</i> , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K- δ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2017, 130, 819-819.	0.6	12
51	Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. <i>Blood</i> , 2018, 132, 2899-2899.	0.6	10
52	Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 207-212.	0.9	9
53	Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 32.	2.8	9
54	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. <i>Blood</i> , 2019, 134, 1619-1619.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. Journal of the National Cancer Institute, 2021, 113, 820-822.	3.0	7
56	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. Blood, 2019, 134, 22-22.	0.6	7
57	TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin. Blood, 2015, 126, 180-180.	0.6	7
58	Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis. Blood, 2020, 136, 35-36.	0.6	7
59	Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features. Blood Cancer Journal, 2020, 10, 116.	2.8	6
60	High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma. Blood, 2019, 134, 2837-2837.	0.6	6
61	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. Blood, 2020, 136, 11-12.	0.6	6
62	Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. Current Hematologic Malignancy Reports, 2016, 11, 224-233.	1.2	5
63	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Blood, 2020, 136, 17-18.	0.6	5
64	How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. Hematology American Society of Hematology Education Program, 2021, 2021, 240-246.	0.9	5
65	<sc>PD</sc> improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome. Cytometry Part B - Clinical Cytometry, 2022, 102, 189-198.	0.7	5
66	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. Blood, 2019, 134, 1555-1555.	0.6	4
67	Successful Treatment of Peripheral T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: A Large Single-Center Experience. Blood, 2015, 126, 4392-4392.	0.6	4
68	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. Blood, 2016, 128, 2955-2955.	0.6	4
69	Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma. Bone Marrow Transplantation, 2018, 53, 654-656.	1.3	3
70	Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation. Blood, 2015, 126, 520-520.	0.6	3
71	Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). Blood, 2016, 128, 1778-1778.	0.6	3
72	Interim PET Evaluation By Deauville Criteria Is an Effective Risk Stratification Tool in PTCL. Blood, 2016, 128, 186-186.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 654-654.	0.6	3
74	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	0.6	2
75	Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT). <i>Blood</i> , 2019, 134, 2826-2826.	0.6	2
76	End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2020, 136, 30-31.	0.6	2
77	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	0.6	2
78	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. <i>Blood</i> , 2016, 128, 1777-1777.	0.6	2
79	TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy. <i>Blood</i> , 2021, 138, 1367-1367.	0.6	2
80	PD-1 blockade for untreated Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 1271-1272.	0.6	1
81	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2834-2834.	0.6	1
82	Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis. <i>Blood</i> , 2019, 134, 2855-2855.	0.6	1
83	The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. <i>Blood</i> , 2016, 128, 921-921.	0.6	1
84	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. <i>Blood</i> , 2019, 134, 2850-2850.	0.6	1
85	Moving Beyond One Size Fits All for T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, , JCO2102463.	0.8	1
86	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2021, 138, 2447-2447.	0.6	1
87	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-38.	0.6	1
88	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	2.8	1
89	NLP Hodgkin lymphoma: can we get away with less?. <i>Blood</i> , 2020, 135, 2329-2330.	0.6	0
90	Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 1649-1649.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. <i>Blood</i> , 2015, 126, 3865-3865.	0.6	0
92	Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 2000-2000.	0.6	0
93	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. <i>Blood</i> , 2015, 126, 2668-2668.	0.6	0
94	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2691-2691.	0.6	0
95	Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1774-1774.	0.6	0
96	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. <i>Blood</i> , 2016, 128, 4119-4119.	0.6	0
97	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.	0.6	0
98	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. <i>Blood</i> , 2021, 138, 2513-2513.	0.6	0
99	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. <i>Blood</i> , 2021, 138, 4578-4578.	0.6	0
100	Clinical Characteristics and Follow-up Post-Surgery of Women with Bia-ALCL Operated at a Single Institution. <i>Blood</i> , 2020, 136, 32-33.	0.6	0